541
Views
40
CrossRef citations to date
0
Altmetric
Review

Cognitive impairment in patients with AIDS – prevalence and severity

&
Pages 35-47 | Published online: 29 Jan 2015

Abstract

The advent of highly active antiretroviral therapy has prolonged the life expectancy of HIV patients and decreased the number of adults who progress to AIDS and HIV-associated dementia. However, neurocognitive deficits remain a pronounced consequence of HIV/AIDS. HIV-1 infection targets the central nervous system in subcortical brain areas and leads to high rates of delirium, depression, opportunistic central nervous system infections, and dementia. Long-term HIV replication in the brain occurs in astrocytes and microglia, allowing the virus to hide from antiviral medication and later compromise neuronal function. The associated cognitive disturbance is linked to both viral activity and inflammatory and other mediators from these immune cells that lead to the damage associated with HIV-associated neurocognitive disorders, a general term given for these disturbances. We review the severity and prevalence of the neuropsychiatric complications of HIV including delirium, neurobehavioral impairments (depression), minor cognitive-motor dysfunction, and HIV-associated dementia.

Introduction

Combinations of antiretroviral drugs administered as highly active antiretroviral therapy (HAART) have decreased the HIV disease-related mortality and the severity of the illness.Citation1 Now, more individuals manage HIV as a chronic disease given there is a decreased progression to AIDS and AIDS dementia. Despite these advances, neurocognitive disturbances from the HIV virus still persist as complex and clinically important problems.

With the prolonged life expectancy of patients to over age 50, age is also a factor in HIV-related cognitive disturbances. An estimated one of every four newly diagnosed HIV infections occurs in older adults.Citation2Citation4 As patients age with HIV, HIV-associated neurocognitive disorders (HANDs) are known to cause significant morbidity and mortality and ultimately accelerate the aging process. Age is a known factor in the progression of HIV seropositivity, with a decreased incubation period from exposure to development of AIDS symptoms,Citation5Citation7 decreased proliferation of T-lymphocytes,Citation8,Citation9 and significant risk of HANDs.Citation7,Citation10,Citation11

HIV reproduces in microglia, the brain’s immune cells, causing central nervous system (CNS) inflammation and progressive cognitive and behavioral changes. Although the clinical definitions have recently changed,Citation12 HAND can range from asymptomatic neurocognitive impairment (ANI) to mild-motor neurocognitive disorder (MMND) with minor concentration and memory problems to HIV-associated dementia (HAD) with global cognitive impairment.Citation13,Citation14

Although somewhat controversial, ANI and MMND appear to be related to glial dysfunction and are diagnosed through neuropsychological tests, while HAD is a clinical diagnosis and may be the result of neuronal cell death.

In addition to age, major depression disorder (MDD) and HAND share common risk factors, including female sex, stage of HIV illness, comorbid illnesses such as Hepatitis B and C, and injected drug use. The Research on Older Adults with HIV study collected self-report data from 2005 to 2006 on depressive symptomology from over 1000 HIV-positive men and women with HIV who had age 50 and older. Based on this study, there appears to be significant correlations with Depression Scale scores, higher disease burden, and cognitive impairment.Citation15

Given that HIV-associated cognitive impairments span the scope of emotional changes, attention, executive dysfunction, and memory, we identify the various types of neuropsychiatric complications. We review the acute changes associated with altered mental status in delirium and the neurobehavioral impairments commonly attributed to major depressive disorder. We discuss the motor and memory dementia spectrum that includes ANI, mild-motor neurocognitive disorder, and HIV-dementia. Our goal is to provide an understanding of the prevalence, severity, diagnosis, and management of these conditions with the goal of helping clinicians identify and distinguish these clinical syndromes in AIDS patients.

Primary psychiatric conditions associated with cognitive impairment

Delirium

Prevalence and severity in HIV infection and AIDS

The most common neuropsychiatric complication in hospitalized patients with AIDS is delirium.Citation16,Citation17 The overall prevalence of delirium in the general community is just 1%–2%, but in the setting of general hospital admission this increases to 14%–24%.Citation18 However, the point prevalence of delirium in hospitalized AIDS patients is estimated to be between 30% and 40%.Citation19 There also appear to be higher rates of new cases of delirium at the time of HIV seroconversion.Citation18,Citation19 Given that delirium is often an acute condition that is present in hospitalized patients with a change in mental status, lifetime prevalence estimates are more difficult and not abundant in the literature. Most studies of AIDS-associated delirium were done in the mid-80s to the late 1990s during the pre-HAART era with a very few updated about the prevalence of AIDS-associated delirium since 2000.

Delirium in HIV patients presents with the same clinical features as in non-HIV-infected individuals and is characterized by a waxing and waning state of inability to attend, disorganized thinking or confusion, and fluctuations in the level of consciousness. Mood and memory changes are common and often have a diurnal variation. Aside from general risk factors such as comorbid medical problems, older age, multiple medications, and previous episodes of delirium, patients with HAD are the highest risk group to develop delirium. The waxing and waning nature of delirium can make it difficult to diagnose as the patients may present completely different mental states to different clinicians depending on when they are evaluated.

Delirium can be a severe problem in those dealing with advanced HIV infection and prolonged immunosuppression.Citation20 Older studies estimated that 46% of institutionalized patients at skilled nursing facilities needed treatment for one or more occurrences of delirium.Citation21 More recent studies have used delirium as a subtle indicator of higher morbidity and mortality in patients who have advanced to AIDS.Citation22,Citation23 Hospitalized patients with AIDS were also found to have increased mortality if delirium complicated their hospital course.Citation22 Age appears to be an independent variable, as delirium may also occur in children with AIDS.Citation24

Clinical symptoms and differential diagnosis

Delirium may resemble other neuropsychiatric conditions and needs to be distinguished from other brain disorders, including MDD, AIDS mania, minor cognitive-motor disorder, HAD, and CNS infection. Delirium is often differentiated from other conditions because of a fluctuation in orientation and awareness, acute onset, and/or a connection to an underlying medical illness. The other disorders have a stable level of consciousness. Delirium can be complicated by an insidious illness or a rapid process. Alterations in circadian rhythms, mood state, and psychomotor speed may be observed. Delusions and hallucinations may also occur, which may be similar to those seen in dementia, depression, manic episodes, and even schizophrenia. Depression is commonly mistaken for delirium when a person is in a hypoactive state. Once the underlying insult is managed, the symptoms tend to resolve fairly rapidly. However, a 20% decrease in survival rate is associated with delayed or missed diagnosis in hospitalized patients.Citation16

Determining the cause of delirium is critical to the management of HIV/AIDS patients. Prior to combination antiretroviral therapy, particular considerations in immunocompromised patients with HIV focused on atypical CNS and systemic bacterial infection with cytomegalovirus encephalopathy, mycobacterium avium, fungal infections, and hypoxia with Pneumocystis pneumonia. With the widespread use of HAART, and a fewer number of AIDS cases, delirium is more commonly associated with toxicity from polypharmacy, HIV-related cerebrovascular disease, and psychoactive drug withdrawal or intoxication.Citation25 Due to the degree of cerebral involvement, HIV/AIDS patients are vulnerable to fluctuations in blood metabolites and hydration status. These variations, along with the HIV virus itself, may contribute to acute global brain dysfunction or encephalopathy, comparable to cytomegalovirus encephalopathy infection.Citation16,Citation26

To clarify the diagnosis, a detailed medical history and evaluation may need to be conducted at two different time points because of the waxing and waning nature of delirium. Several assessment tools have been studied in delirium and prove to be reliable in examining HIV/AIDS patients. These include the Folstein Mini-Mental Status Examination, the Delirium Rating Scale, and the Memorial Delirium Assessment Scale.Citation27 Depending on the nature of the impairment, additional brain imaging may be warranted to look for signs of bleeding or infection, which may involve blood cultures, computed tomography, or magnetic resonance imaging (MRI). Although non-specific, electroencephalography (EEG) is being employed more often because it identifies electrical brain activity with a pattern different from that seen in seizure disorders. The diffuse cerebral dysfunction seen in delirium often causes slowing of EEG rhythms, and when present, may be helpful in supporting the diagnosis.

Approaches to management and treatment

Delirium in HIV/AIDS is treated in a similar manner to delirium in general medical conditions. The most effective initial step, whenever possible, is to pinpoint and remove the underlying, contributing factors. The next priority is to reorient the patient through environmental cues and initiate pharmacotherapy when indicated. The most studied antipsychotic treatment has been low-dose haloperidol. In double-blind, randomized control trials, open-label trials and others of oral and intramuscular administrations of the drug showed resolution of symptoms within 24 hours at lower doses with minimal side effects.Citation27 Second-generation or atypical antipsychotics have been used in delirium, but are avoided as the first-line treatment because of adverse events in vulnerable populations and the elderly.Citation28 A meta-analysis of prospective studies concluded that the first-generation antipsychotics haloperidol and chlorpromazine and the second-generation risperidone, quetiapine, and olanzapine were helpful in resolving delirium symptoms.Citation29

Treatment with antipsychotic medication requires awareness of the higher susceptibility of patients with HIV to neuroleptic-induced extrapyramidal symptoms (EPS), even with exposure to drugs with low potential for inducing EPS.Citation30,Citation31 Patients with AIDS-related psychosis are more sensitive to EPS and respond to lower than standard doses of antipsychotics.Citation25,Citation32 If indicated, typical neuroleptic medications should be used at the lowest dosage for the briefest duration possible. Increased susceptibility to EPS has been particularly notable with the use of conventional neuroleptic medications and has limited the dosage used to treat patients. Extreme sensitivity to EPS is encountered in patients with HIV-dementia.Citation32,Citation33 Marked neuronal degeneration in the basal ganglia of patients with HIV may contribute to these findings because of the accompanying dopaminergic neuron destruction and/or alteration.Citation34,Citation35 Dyslipidemia and hyperglycemia are also potential side effects when using antipsychotics in the setting of antiretroviral therapy.Citation36

To date, there have been a few randomized controlled trials in delirious patients with AIDS with documented efficacy of low-dose haloperidol and chlorpromazine. Benzodiazepines and anticholinergic medicines may contribute to delirium in some cases. These should be used minimally except when alcohol or benzodiazepine withdrawal is the precipitating factor.Citation21 Lorazepam appeared to be ineffective in one study because of the associated and significant side effects; however, lorazepam was reported to be useful in cases of AIDS-associated psychosis with catatonia.Citation28 However, in a systematic review, patients with AIDS treated with lorazepam developed confusion and were oversedated, resulting in discontinuation of the drug.Citation26 Older case reports indicate that molindone (not currently manufactured) and ziprasidone are of benefit for HIV-associated psychosis and have minimal EPS.Citation37

Atypical antipsychotics are generally preferred because of lower risk for EPS. Terminal delirium in AIDS, as in other terminal diseases, is more refractory to treatment. The use of physical restraints has grown out of favor as tends to worsen agitation and hospitalized patients are susceptible to pressure ulcers. In cases of severe agitation and physical violence, closely monitored restraints may be necessary when other alternatives are inadequate.

Major depression

Prevalence and severity in HIV infection and AIDS

Depression is a significant problem encountered by HIV and AIDS patients. MDD in HIV-infected patients has an estimated prevalence of 19%–43% depending on the region examined.Citation38,Citation39 The high prevalence may be due in part because of the populations at risk for HIV infection. Homosexual men and patients with substance use disorders tend to have elevated prevalence of MDD. A detailed review of 10 studies comparing HIV-positive and at-risk HIV-negative patients found that there were twice as many cases of MDD in patients infected with HIV compared to controls.Citation40

Lyketsos et al reported an association between depression and HIV infection as early as 1993 and speculated that MDD was a risk factor for developing HIV.Citation41 Since that time, other studies have estimated depression rates between 15% and 40% in HIV-seropositive individuals depending on the geographic location and demographics of the group studied.Citation42Citation44 The rates of MDD surpassed 50% in outpatients with HIV pursuing mental health treatment.Citation44,Citation45 A sevenfold increase was found in the lifetime prevalence of affective illness, when screening patients for HIV, even without substance abuse issues.Citation46

When examining severity of major depression of HIV/AIDS, most of the studies focus on the association of mood disorders with higher rates of disease transmission, lower rates of compliance, and psychological distress from the disease. Major depression makes individuals more susceptible to contracting HIV and AIDS because of its effect on behavior. Depression factors into HIV risk since it often impacts insight and judgment in decision-making and may exacerbate substance abuse.Citation42,Citation47,Citation48 In this way, the vulnerability from MDD has been termed to be “a vector of HIV transmission” by some experts in the field.Citation48,Citation49 MDD not only serves as a risk for perpetuation of the HIV epidemic but also is a complication preventing effective treatment.Citation50 MDD has been associated with more rapid HIV disease progression to AIDS and higher mortality rates.Citation51,Citation52

Acting through diverse biological mechanisms, the HIV virus influences the brain’s immune system, and the increased inflammatory disease burden may lead to increased risk of depression and other mood and psychotic symptoms. AIDS patients with high viral loads have been recognized as a group with a high risk of psychological distress,Citation50,Citation53 and high prevalence rates of suicide have been reported among HIV-infected patients in general.Citation36,Citation54 The HIV virus in the CNS appears to directly impact subcortical areas of the brain that also affect mood, the stress response, and behavior. The stress on the immune system, injury to the brain’s mood center, and social stigma of HIV infection collectively promote social isolation, behavioral changes, and impulsive behaviors. Some experimental studies support this therapy. The Multicenter AIDS Cohort Study showed that rates of depression increased 2.5-fold as CD4 cells declined to fewer than 200/mm3 just before patients developed AIDSCitation53 suggesting that lower CD4 cell counts predict increased rates of depression. A decreased number of natural killer T-cells available to mount a cytokine responseCitation51 and diminished levels of CD4 cells were identified in depressed patients with HIV.Citation47 Therefore, depression and HIV appear to share common mechanisms that contribute to an additive risk of contracting HIV/AIDS and susceptibility to MDD when both illnesses are present.

Symptoms and differential diagnosis

The diagnosis of MDD in the HIV/AIDS clinic is complicated by the high frequency of depressive symptoms that are associated with these other problems. Routine screening for depression in people with HIV can effectively identify cases. Both the Patient Health Questionnaire-9 and Patient Health Questionnaire-2 have been valid and reliable.Citation55,Citation56

Unlike the low mood, poor sleep, poor appetite, and changes in self-attitude described in classic major depression, HIV-infected patients with major depression often present to their primary care physician with multiple somatic symptoms, including headache and gastrointestinal disturbances. With this constellation of vague symptoms, it is necessary to distinguish MDD from normal sadness, delirium, substance withdrawal and/or intoxication, opportunistic CNS infection, and dementia. Physiological disturbances resulting from malnutrition, wasting syndromes, and medication side effects also need to be ruled out.

Depression was at one time termed “pseudo-dementia” because of its ability to mimic cognitive as well as behavioral impairment. Therefore, problems with executive functioning, apathy, short-term memory loss, inattention, and sometimes general confusion are symptoms of depression mistaken for dementia.

Given the burdens of HIV in the later stages resulting in AIDS, clinicians often focus on the medical comorbidities, and the depression symptoms may be overlooked. Opportunistic infections, including CNS lymphoma, Cryptococcal meningitis, and toxoplasmosis, are more prevalent in AIDS and present a challenge to individual management and treatment of depression. Neurosyphilis is rare but common in AIDS and has been a long-standing imitator of MDD and psychotic symptoms. Relapse use of cocaine and the subsequent withdrawal can trigger depression-like symptoms with activated confusion that may be mistaken for dementia.

Demoralization, feeling hopeless or sad after contracting HIV, or having difficulty coping with the stress from the illness, is one of the most common feelings in HIV/AIDS. Clinically, this experience is referred to as “an adjustment disorder”.Citation53 Given the overlap with depression symptoms, systematic criteria must be applied for HIV patients to distinguish between the demoralization in adjustment disorder and MDD. Over 50% of outpatients presenting to an urban HIV clinic with depressive complaints were found to have an adjustment disorder alone.Citation57 Unlike MDD, demoralization does not usually involve a change in self-concept or cognitive deficits. Other issues that arise with demoralization include guilt over acquiring HIV, guilt over infecting others, and anger at the source of disease, at oneself, or at God. The diagnosis of HIV infection may lead to precipitous revelation of hidden sexual or drug abuse behavior, eliciting shame and self-loathing. The stigma of HIV may lead to rejection or abandonment by loved-ones, and shunning by wider society, making patients feel socially isolated. Despite the development of HAART, some patients become hopeless, turn out nihilistic and forgo HIV treatment, evolve into a depressed state, and ultimately need antidepressant treatment.

Several drugs used in patients with HIV have been reported to produce a major depressive episode. Interferon, metoclopramide, sulfonamides, and steroids are associated with inducing depression symptoms in healthy individuals in addition to those with HIV. Efavirenz, a nonnucleoside reverse transcriptase inhibitor, has been associated with depression symptoms in AIDS patients during the first 4 weeks of useCitation58 while long-term use over a 3-year or more period was associated with anxiety instead of depression.Citation59,Citation60 The treatment of drug-related depression symptoms is to decrease or eliminate the medication. Sometimes, when the medication is essential for HIV/AIDS treatment, physicians start antidepressant therapy to manage the mood symptoms.

Management

Once identified as MDD and distinguished from other illnesses, the goal is early treatment. HIV-positive patients appear to respond to antidepressant treatment at a level comparable to depressed patients without HIV and those with other comorbid illnesses.Citation45,Citation61,Citation62 While several studies in the HIV/AIDS population reported a potential benefit to the tricyclic antidepressant (TCA) class of antidepressants, to date there does not appear to be a response difference between any specific TCA, selective serotonin reuptake inhibitors, or any other class of antidepressants. With all depressed patients, nonadherence is the most common reason for ineffective drug treatment, and adverse effects are the most common reason for nonadherence. Because HIV- infected patients are likely to be more sensitive to side effects, antidepressants should be started at subtherapeutic dosage and raised slowly. Clomipramine and imipramine are thought to have anti-inflammatory and neuroprotective effects by modulating glial cell activation in the CNS.Citation63,Citation64 However, TCAs have anticholinergic and other adverse effects that may sometimes make them difficult to use in patients with AIDS. Open-label trials of fluoxetine, sertraline, and paroxetine in various stages of HIV illness reported response rates (including affective and somatic depressive symptoms) between 70% and 90%, and all the medications were well tolerated.Citation61,Citation65,Citation66 One double-blind, placebo-controlled study of fluoxetine found significant response.Citation67 Other similarly designed trials in HIV-infected users of intravenous cocaine and opioids showed significant reduction in depressive symptoms with fluoxetine compared with placebo or other antidepressant medications.Citation25,Citation66,Citation68 Supportive group psychotherapy and fluoxetine were found to be superior to placebo and group therapy for a population of homosexual or bisexual men with HIV, and patients with more severe symptoms tended to achieve greater benefits from medication.Citation50,Citation69

The side effects of certain antidepressants can render them advantageous or disadvantageous in particular patients with HIV. For example, selective serotonin reuptake inhibitors are best avoided in patients with chronic diarrhea. Sedating antidepressants should be avoided in patients with weakness, lethargy, orthostasis, or other risks for falls. TCAs should be avoided with oral candidiasis because of the aggravating effect of dry mouth on thrush. In cases of anorexia or cachexia, antidepressants with appetite-stimulating effects are best selected.

An important issue is the interaction of antidepressants and HAART medications. Treatment with HAART was linked with significant improvement in symptoms of depression but did not necessarily have a causal relationship.Citation50,Citation61,Citation70 HAART failure or medication nonadherence appears to be magnified in untreated depression.Citation20 Although debated and little evidence indicates that antidepressants cause fluctuations in CD4 cell counts,Citation71,Citation72 some experts believe that medication compliance improves with antidepressant treatment.Citation45,Citation50

However, the clinical significance of some of these drug–drug interactions has not yet been clearly established and future studies may need to focus on potential dose adjustments in AIDS patients.

Neurocognitive conditions associated with HIV

Minor cognitive-motor disorder

Prevalence and severity

The nature of HIV-related neurocognitive disorders has rapidly evolved with the widespread use of antiviral treatment. With the contributions of aging, immune reactivation, antiviral-induced mitochondrial toxicity, gut leakiness, and chronic inflammation, the characteristics of these conditions have become much more heterogeneous. Overall, these conditions have become less “subcortical” and have a more unpredictable course with worsening and improvement in some patients over time.

Mild neurocognitive disorder and “minor” cognitive-motor disorder are similar terms used for the early stages of a spectrum of “dementia” syndromes seen in HIV disease. Unlike HAD, a late-stage disorder that we will describe in more detail in the next section, MMND may present at the beginning of HIV disease. However, the symptoms are subtle or may be elusive. MMND resembles HIV-dementia because of memory loss, difficulty with executive functioning, decreased fine motor skills, and gait disturbance. These are usually isolated complaints and have a mild degree of impairment. MMND is now regarded as part of the spectrum of HAD. With changes in terminology, its description as “minor cognitive-motor disorder” in the literature had fallen out of use.Citation13,Citation14

MMND appears to occur frequently in AIDS patients with prevalence rates approaching 60% in the AIDS population.Citation73 Because the symptoms may be overlooked, the incidence and recurrence rates have been difficult to estimate, especially in the early stages. Current research is looking to whether MMND inevitably leads to HIV-dementia. The effect of HAART now confounds this question; data from earlier in the epidemic cannot be reasonably compared with the current data. Early studies suggest that some patients remain stable with mild cognitive and motor symptoms while others advance to dementia.Citation74 There are not any current markers to predict long-term outcome of the disease.

Differential diagnosis

The motor symptoms in MMND, although not always detected, often present before the cognitive symptoms. HIV patients may notice a fine tremor, difficulty typing, or repeating fine movements. The gait disturbance in early MMND may be a slight shuffle when walking or a wobble when running. The motor involvement may be mistaken for Parkinson’s or a drug-induced tremor.Citation75Citation77 Clinical features that resemble Parkinson’s disease occur frequently with HIV-dementia and are attributed to disruption of the dopamine pathway.Citation78 The motor symptoms may be attributed to side effects of the HIV medications, and therefore MMND can be overlooked. The physical examination may reveal frontal release signs; abnormal eye movements; and the inability to perform rapid, alternating movements, all of which worsen as the disease progresses.Citation73,Citation79 Opportunistic infections, especially in AIDS, should be ruled out with brain imaging. The HIV virus targets the brain and may produce these symptoms.Citation80,Citation81 Neuropsychiatric testing is helpful because it can pick up the discrete signs of short-term memory loss, inattention, and difficulties with activities of daily living associated with MMND. With the initial diagnosis of AIDS, with little to no signs of cognitive problems, decreased psychomotor speed has become the primary predictor of whether patients progress to dementia within the next 2 years.Citation73,Citation79 Recently, the Montreal Cognitive Assessment examination, a valid and reliable screening test for early cognitive impairment in elderly patients, was able to detect mild cognitive problems in HIV-positive patients with self-reported cognitive problems.Citation82 Over 50% of these patients actually had some minor deficits in their cognitive abilities, not noted on any other part of their physical or mental status examination.Citation82 With decades between some of the investigations, newer measurements are needed to identify cognitive problems at the early stages of HIV and AIDS.

Management

No controlled treatment data are available specifically for MMND disorder. Psychostimulants also have been evaluated for treatment of fatigue, cognitive impairment, and depression in patients with HIV. Open-label trials report an 85% mood response rate in patients with HAD taking methylphenidateCitation17 and a 95% mood response rate in men with AIDS taking dextroamphetamine.Citation66,Citation83 A double-blind trial showed a significant response to dextroamphetamine compared with placebo in patients with AIDS and major depression, subthreshold major depression, or dysthymia.Citation83 Double-blind comparisons of methylphenidate, pemoline, and placebo in patients with HIV (most with AIDS) found improvement in both depressive symptoms and fatigue.Citation28

HIV-associated neurocognitive disorders

Prevalence and severity

HAND is an all-inclusive designation given to the spectrum of neurological conditions that cause cognitive impairment and result from the immune system’s response to HIV infection and metabolic encephalopathy. Ranging from the least to the most severe, HAND may refer to mild neurocognitive disorder (MND), HIV encephalopathy, HAD, or AIDS dementia complex (ADC). For our purposes, we reviewed mild cognitive impairment when discussing MND. We will focus on AID- associated dementia and will review more severe impairment.

In 1986, HAD was reported in up to two-thirds of AIDS patientsCitation84 but it is less frequent now in patients receiving HAART. HAD became the explanation for severe cognitive impairment and dementia in persons younger than age 60.Citation85 However, its frequency among patients with otherwise asymptomatic HIV infection or T-helper cell number more than 500 cells/mm3 was probably less than 5% in a community sample.Citation86 In the Multicenter AIDS Cohort Study, the incidence of HAD declined 50% from 1990 to 1992 and 1996 to 1998, a period during which effective antiretroviral therapy was used.Citation86,Citation87

With the widespread use of HAART in developing countries in the mid-1990s, there was a dramatic fall off in the rates of AIDS dementiaCitation88 with cases usually associated with specific risk factors including female sex, being elderly, higher HIV viral titers, lower socioeconomic group, substance abuse, and iron-deficiency anemia. In the post-HAART era, minor-motor neurocognitive disorder and depression are more predictive of severity of HIV-dementia later in the disease course.Citation73,Citation79,Citation89 HAD is generally observed in seropositive individuals who have CD4 cells at an all-time level below 200/mm3.

The overall incidence and prevalence rates of HIV-dementia in the post-HAART era vary greatly by geography, treatment, and risk factors studied, as well as whether patients are sampled in the community, a clinic, or a hospital. Studies from 1996 to 2002 in Italy estimate rates of cognitive impairment and dementia as 55% and 10%, respectively.Citation90 In the country of Georgia, an estimated 25% of HIV/AIDS patients have developed dementia from the disease.Citation91 Of the women in Puerto Rico who were determined to be “at risk” for development of dementia based on their HIV status, 49% had cognitive impairment and 29% had dementia.Citation92 This is in contrast to what is observed in hospitalized HIV/AIDS patients in Kenya, where dementia is rarely detected.Citation93 The factors that contribute to the variance of prevalence and incidence rates, whether related to the disease, environment, or diagnostic tools used, require further investigation.

Prevalence associated with HAART and substance abuse

While much of the discussion of HAND is focused on the role of HAART therapy in reducing the number of new cases of HAND in AIDS, the prevalence rate of 50% has remained stable.Citation14,Citation94,Citation95 With patients living longer on HAART, there is some concern that AIDS dementia prevalence will increase in association with the length of infection or with residual virus confined to the CNS.Citation80,Citation94 Newer studies now suggest that HAART regimens, with long-term use, may also generate cognitive impairment symptoms.Citation80,Citation96 The toxicity of HAART may create a reservoir that reduces the severity of opportunistic infections, but HAART has not changed the degree of microglial activation or neuroinflammation generated by the HIV virus.Citation64 To date, HAART has been linked with inflammation in the temporal cortex and the hippocampus, thus suggesting an association with working memory. Prior to the HAART era, inflammation was mainly seen in the basal ganglia and linked to more motor symptoms. HAART is now linked to an increased production of brain lymphocytes that lead to a transient motor-cognitive disorder that looks like amyotrophic lateral sclerosis.Citation97 In addition, there appears to be a synergistic effect of HIV and drug abuse on expression of major histocompatibility complex II and CD68 inflammatory markers, leading to increased adverse effect on the brain than either individual insult on its own.Citation98 As one review points out, with the longevity of HIV-positive patients, we may not be able to fully understand the combined role of HAART, drug abuse, and HIV until older patients and patients in the post-HAART era undergo postmortem pathological evaluations.Citation99 Therefore, more research is needed about the relationship of CNS inflammation to HAART therapy.

Symptoms and differential diagnosis

Understanding the mechanisms that contribute to HAD would help with better identification of the symptoms and clinical management. Although an active area of investigation, the prevailing theories involve infection of the virus in brain macrophages and activated microglia in the CNS.Citation100,Citation101 Neurons, astrocytes, and oligodendrocytes do not appear to be directly infected by the virus. A cascade of chemokines and cytokines mediated by activated microglia cells leads to cell death through decreased arborization of neurons. Therefore, the immune system involvement may explain the subtlety of the clinical symptoms and global progression of the dementia over a period of time.

At the early stages, the chief complaints in HAD are a combination of short-term memory impairment, low mood, and motor slowing. At the initial onset, like MND, the symptoms may seem to be mild, but involve some disruption of the normal daily routines of managing financial obligations, following directions, reading, remembering names and dates, and remembering appointments. These symptoms are often indistinguishable from other types of dementia, misinterpreted as lethargy or missed because the signs are below clinical detection. As symptoms become more profound, they involve multiple regions of the brain that control long-term memory, name and facial recognition, language expression and comprehension, and organization and management.

Like many neuropsychiatric complications of HIV and AIDS, HAD shares symptoms common to depression, anxiety, and psychotic disorders that may be confused with other brain illnesses. Major depression symptoms of low or irritable mood, loss of pleasure and enjoyment, changes in sleep, weight loss, and tearful episodes are prevalent in HAD.Citation42 In place of sadness, patients may be apathetic, retreat from their usual interests, and become emotionally distant and socially withdrawn. Anxiety, either from frustration with memory loss or general restlessness, appears to be universal in dementia. A subset of patients may develop paranoid delusions, visual or auditory hallucinations, or mania-type symptoms that develop into a psychosis that requires prompt treatment.

With the changes in mood, cognition, and altered perception of reality, some believe HAD may be a contributing factor to suicide in AIDS patients.Citation36 HAD has also developed in the presence of milder immunosuppression.Citation95,Citation102,Citation103 With this compilation of symptoms, HAD appears to quickly evolve into AIDS dementia complex and ultimately ends in death after 2 years of diagnosis.Citation103

Evaluation and management

Cognitive screening tools have been recently reviewed.Citation104Citation106 The Mini-Mental Status Examination is a well-known, fast, and easy screening tool for cognitive impairment in general, but appears to be less sensitive in HIV-dementias.Citation104 A useful bedside screening tool, the Modified HIV Dementia Scale, has been shown to be the most specific and valid assessment tool that can be repeated on serial occasions to follow the trend of symptoms and evolution of the dementia in multiple population types.Citation107,Citation108 Newer studies show the Montreal Assessment Scale (Montreal Cognitive Assessment) has an advantage in that it is free and evaluates multiple cognitive domains in one sitting. Scores of less than 26 indicate a referral for additional neuropsychological assessments for cognitive deficits.Citation82,Citation105 In the course of neuropsychiatric testing, patients with signs of dementia will often have difficulty on timed and repetitive activities, particularly the Grooved Pegboard assessment and the oral Trail Making B task. The next step is brain MRI to look for any reversible pathology that may argue against the diagnosis.

Typical findings on MRI in the HIV/AIDS population with HAD include significant white matter lesions as well as cortical and subcortical atrophies.Citation109,Citation110 These abnormalities may appear as discreet foci, as patchy regions of confluent involvement, or as diffuse parenchymal involvement.Citation109,Citation110 Partial improvement of MRI signal abnormalities, worsening of atrophy, and prominent white matter intensities have been summarized in reviews of individuals with HAD taking zidovudine.Citation109 MRI also has been suggested to be of utility in monitoring HAD therapy with HAART.Citation111

Various functional neuroimaging techniques such as positron emission tomography, single-photon emission computed tomography, and magnetic resonance spectroscopy have shown alterations in cerebral blood flow and metabolic patterns in the brains of individuals infected with HIV.Citation112Citation114 Most of these studies were done in patients with dementia or other cognitive impairment,Citation115 but other magnetic resonance spectroscopy investigations showed abnormalities in patients with no cognitive deficit.Citation114,Citation116,Citation117 Increased brain activation on functional MRI during working memory was found in patients with early HIV cognitive disturbance.Citation114 Further studies showed increased stimulation areas in the brain on functional MRI in HIV-positive patients that predated clinical signs or deficits on cognitive tests.Citation118

Treatment

Controlled trials for HAD have been reviewed elsewhere.Citation25,Citation119,Citation120 Intensification of antiretroviral therapy and associated control of viral load are associated with significantly lower risk for progression to HAD. Furthermore, HAART improves learning and memory in patients with HAD.Citation99,Citation121

Controversy exists regarding the duration of treatment and outcome of dementia. The long-term effect of HAART on the course of HAD remains undetermined, with some evidence of ongoing HIV-related cognitive damage despite more than 3 years of potent antiretroviral treatment.Citation122 The only other controlled trial of antiretroviral drugs compared effective antiviral therapy with and without added high-dose abacavir, but the study did not detect further cognitive improvement. A newer study was able to show some improvements in neurocognitive function over the first year after initiating antiretroviral therapy, but only in neuroasymptomatic HIV-infected subjects.Citation123

Antiretroviral agents with and without good CNS penetration, combined with HAART, appear to be effective in treating the virus in the CNS.Citation124 Drugs that cross the blood–brain barrier and accumulate in the cerebrospinal fluid include abacavir, stavudine, and zidovudine (nucleoside reverse transcriptase inhibitors) and the nonnucleoside nevirapine. Despite these theoretical CNS considerations, there is little evidence suggesting an improved outcome for any particular antiretroviral regimen. However, the higher proportions of patients with HAD compared with other AIDS-defining illnessesCitation103 suggest that HAART may not be as effective for treating HAD.

Various clinical trials have evaluated neuroprotective medications for HAD including nimodipine, antioxidants, platelet-activating factor antagonist, T-peptide, and memantine, but none were shown to be efficacious.Citation84,Citation125Citation127

Dopamine-enhancing agents, although assumed to be related to the movement disorder in HAD, do not appear to be effective treatments in adults, despite earlier success in pediatric patients with movement disorders and HIV.Citation128,Citation129 Stimulant medications tested in some HIV patients have demonstrated improvement in cognitive abilities,Citation130 but others have noted apparent acceleration of HAD in conjunction with psychostimulant therapy.Citation28,Citation131 There have not been more recent reported clinical trials with dopamine agonists or stimulants.

Risperidone and clozapine have been described in case reports of HAD with psychosis. Treatment with these antipsychotic agents showed marked resolution of psychotic symptoms and fewer extrapyramidal motor symptoms.Citation32,Citation132,Citation133

In summary, the best management for HAD is to provide an ideal HAART regimen, establish a good medication adherence plan, and rapidly manage any related symptoms.

Conclusion

Neuropsychiatric complications are highly prevalent in HIV/AIDS patients. The foundation for this area of research was laid decades ago. With the decreased incidence of AIDS and AIDS-related complications after the implementation of HAART, there appears to be less research in the neuropsychiatric impairments in AIDS and few new studies to help further expand the field. Given the growing population of individuals aging with HIV, there are still questions that need to be answered about the pathophysiology and progression of neurocognitive disorders in advanced HIV.

Although the percentage of AIDS patients with HANDs has been reduced, this is at significantly lower rate of decline than similar AIDS-defining illnesses. This observation suggests that CNS eradication of HIV is becoming more challenging with current antiretroviral regimens. It has been proposed that increasing resistance to HAART regimens may be linked to this possible evolution.Citation95 In the Multicenter AIDS Cohort Study from 1990 to 1998,Citation86 the proportion of cases of HAD in individuals with CD4 cell markers between 201 cells/mm3 and 350 cells/mm3 was higher in the period of 1996–1998 compared with the early 1990s. This implies that screening for all HAND should be extended to individuals with CD4 cell counts less than 350 cells/mm3.Citation95 The extended survival that antiretroviral regimens have offered patients also may increase their vulnerability to developing dementia rather than dying secondary to other fulminate complications.Citation95

As we make progress in the treatment of HIV/AIDS and the clinical symptoms evolve, more research will be needed on preventative measures to delay the progression of the CNS involvement and minimize the morbidity and mortality seen in HIV-associated neurocognitive disorders.

Acknowledgments

Thanks to Dr Amanda Brown and Dr Justin McArthur for their support in this research through the 5R25 80661 Translational Research in NeuroAIDS Program. This work was supported in part by the Johns Hopkins University Mosaic Initiative Faculty Development Award to CCW and a grant from the Women’s Hospital Foundation to the Neuropsychiatry Program at Sheppard Pratt Hospital.

Disclosure

The authors report no conflicts of interest in this work.

References

  • UNAIDS2013 UNAIDS Report on the Global AIDS Epidemic2013 Available form: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdfAccessed May 27, 2013
  • Center for Disease Control (CDC)HIV Surveillance Report: Diagnoses of HIV Infection and AIDS in the United States and Dependent AreasAtlanta, GAUS Department of Health and Human Services, CDC2005 [online]Atlanta, GAUS Department of Health and Human Services, CDC2011
  • SimoneMJAppelbaumJHIV in older adultsGeriatrics2008631261219061274
  • NguyenNHolodniyMHIV infection in the elderlyClin Interv Aging20083345347218982916
  • ZablotskyDKennedyMRisk factors and HIV transmission to midlife and older women: knowledge, options, and the initiation of safer sexual practicesJ Acquir Immune Defic Syndr200333Suppl 2S122S13012853861
  • ButtAMNandwaniRSexually transmitted diseases in HIV-1-infected patientsLancet20013579267153311386292
  • McArthurJCSacktorNSelnesOHuman immunodeficiency virus-associated dementiaSemin Neurol199919212915010718534
  • JusticeACMcGinnisKAAtkinsonJHPsychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site StudyAIDS200418Suppl 1S49S5915075498
  • GoodkinKWilkieFLConchaMAging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortalityJ Clin Epidemiol200154Suppl 1S35S4311750208
  • ValcourVShikumaCShiramizuBHigher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 CohortNeurology200463582282715365130
  • JanssenRSSt LouisMESattenGAHIV infection among patients in US acute care hospitals. Strategies for the counseling and testing of the hospital patients. The Hospital HIV Surveillance GroupN Engl J Med199232774454521625734
  • AntinoriAArendtGBeckerJTUpdated research nosology for HIV-associated neurocognitive disordersNeurology200769181789179917914061
  • HRSAHIV-Associated Dementia and Other Neurocognitive DisordersGuide for HIV/AIDS Clinical Care, 2014 Available from: http://hab.hrsa.gov/deliverhivaidscare/2014guide.pdfAccessed October 27, 2014
  • CrossSOnenNGaseAOvertonETAncesBMIdentifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scaleJ Neuroimmune Pharmacol2013851114112224114509
  • HavlikRJBrennanMKarpiakSEComorbidities and depression in older adults with HIVSex Health20118455155922127042
  • SonnevilleRFerrandHTubachFNeurological complications of HIV infection in critically ill patients: clinical features and outcomesJ Infect201162430130821329724
  • FernandezFLevyJKSamleyHREffects of methylphenidate in HIV-related depression: a comparative trial with desipramineInt J Psychiatry Med199525153677649718
  • InouyeSKDelirium in hospitalized older patients: recognition and risk factorsJ Geriatr Psychiatry Neurol199811Fall 3118125 discussion 157–1589894730
  • PerrySMarottaRFAIDS dementia: a review of the literatureAlzheimer Dis Assoc Disord1987142212353331119
  • AngelinoAFTreismanGJIssues in co-morbid severe mental illnesses in HIV infected individualsInt Rev Psychiatry20082019510118240066
  • UldallKKBerghuisJPDelirium in AIDS patients: recognition and medication factorsAIDS Patient Care STDS199711643544111361865
  • UldallKKHarrisVLLalondeBOutcomes associated with delirium in acutely hospitalized acquired immune deficiency syndrome patientsCompr Psychiatry2000412889110741884
  • UldallKKRyanRBerghuisJPHarrisVLAssociation between delirium and death in AIDS patientsAIDS Patient Care STDS20001429510010743522
  • HatherillSFlisherADelirium in children with HIV/AIDSJ Child Neurol200924787988319299649
  • HillLLeeKCPharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychoticsAnn Pharmacother2013471758923341158
  • CandyBJacksonKCJonesLLeurentBTookmanAKingMDrug therapy for delirium in terminally ill adult patientsCochrane Database Syst Rev201211CD00477023152226
  • BreitbartWMarottaRPlattMMA double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patientsAm J Psychiatry199615322312378561204
  • BreitbartWRosenfeldBKaimMFunesti-EschJA randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus diseaseArch Intern Med2001161341142011176767
  • SeitzDPGillSSvan ZylLTAntipsychotics in the treatment of delirium: a systematic reviewJ Clin Psychiatry2007681112117284125
  • ValcourVWattersMRWilliamsAESacktorNMcMurtrayAShikumaCAging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapyJ Neurovirol200814536236718989814
  • KellyDVBeiqueLCBowmerMIExtrapyramidal symptoms with ritonavir/indinavir plus risperidoneAnn Pharmacother200236582783011978161
  • DolderCRPattersonTLJesteDVHIV, psychosis and aging: past, present and futureAIDS200418Suppl 1S35S4215075496
  • FernandezFLevyJKMansellPWManagement of delirium in terminally ill AIDS patientsInt J Psychiatry Med19891921651722681028
  • ItohKMehraeinPWeisSNeuronal damage of the substantia nigra in HIV-1 infected brainsActa Neuropathol200099437638410787036
  • FerrandoSJWapenyiKPsychopharmacological treatment of patients with HIV and AIDSPsychiatr Q200273Spring 1334911780596
  • CarricoAWJohnsonMOMorinSFCorrelates of suicidal ideation among HIV-positive personsAIDS20072191199120317502730
  • LesoLSchwartzTLZiprasidone treatment of deliriumPsychosomatics2002431616211927760
  • CysiqueLADeutschRAtkinsonJHIncident major depression does not affect neuropsychological functioning in HIV-infected menJ Int Neuropsychol Soc200713111117166298
  • GibbieTHayMHutchisonCWMijchADepression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDSSex Health20074422723218082064
  • CieslaJARobertsJEMeta-analysis of the relationship between HIV infection and risk for depressive disordersAm J Psychiatry2001158572573011329393
  • LyketsosCGHooverDRGuccioneMDepressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort StudyJAMA199327021256325677901432
  • WatkinsCCTreismanGJNeuropsychiatric complications of aging with HIVJ Neurovirol201218427729022644745
  • RabkinJGWagnerGJMcElhineyMCRabkinRLinSHTestosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo- controlled trialJ Clin Psychopharmacol200424437938515232328
  • American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, 4th Edition – Text Revision (DSMIV-TR)Washington, DCAmerican Psychiatric Association2000
  • WatkinsCCPieperAATreismanGJSafety considerations in drug treatment of depression in HIV-positive patients: an updated reviewDrug Saf201134862363921751824
  • Nakimuli-MpunguEMusisiSKatabiraENachegaJBassJPrevalence and factors associated with depressive disorders in an HIV+ rural patient population in southern UgandaJ Affect Disord20111351–316016721851986
  • SledjeskiEMDelahantyDLBogartLMIncidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIVAIDS Patient Care STDS2005191172873616283833
  • TsaiACMimiagaMJDilleyJWDoes effective depression treatment alone reduce secondary HIV transmission risk? Equivocal findings from a randomized controlled trialAIDS Behav20131782765277223975476
  • TreismanGJAngelinoAFHuttonHEPsychiatric issues in the management of patients with HIV infectionJAMA2001286222857286411735762
  • HimelhochSBrownCHWalkupJHIV patients with psychiatric disorders are less likely to discontinue HAARTAIDS200923131735174219617816
  • AlciatiAGalloLMonforteADBrambillaFMelladoCMajor depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patientsHum Psychopharmacol2007221334017191264
  • IckovicsJRHamburgerMEVlahovDMortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research StudyJAMA2001285111466147411255423
  • LyketsosCGHooverDRGuccioneMChanges in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort StudyAm J Psychiatry199615311143014378890676
  • SherrLHardingRLampeFClinical and behavioural aspects of aging with HIV infectionPsychol Health Med200914327327919444705
  • MaoYGeXFrankCLDisrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signalingCell200913661017103119303846
  • HirshfieldSWolitskiRJChiassonMARemienRHHumberstoneMWongTScreening for depressive symptoms in an online sample of men who have sex with menAIDS Care200820890491018720088
  • LyketsosCGHansonAFishmanMMcHughPRTreismanGJScreening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presenceInt J Psychiatry Med19942421031137960418
  • CliffordDBEvansSYangYImpact of efavirenz on neuropsychological performance and symptoms in HIV-infected individualsAnn Intern Med20051431071472116287792
  • JournotVCheneGDe CastroNUse of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099Clin Infect Dis200642121790179916705588
  • CliffordDBEvansSYangYAcostaEPRibaudoHGulickRMLong-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)HIV Clin Trials200910634335520133265
  • FerrandoSJFreybergZTreatment of depression in HIV positive individuals: a critical reviewInt Rev Psychiatry2008201617118240063
  • AkenaDSteinDJJoskaJDoes screening HIV-positive individuals in Uganda for major depressive disorder improve case detection rates and antidepressant prescription?AIDS Behav20121782802280723247361
  • HuangTLLeuHSLiuJWLymphocyte subsets and viral load in male AIDS patients with major depression: naturalistic studyPsychiatry Clin Neurosci200660668769217109702
  • HarezlakJBuchthalSTaylorMPersistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatmentAIDS201125562563321297425
  • RabkinJGRabkinRHarrisonWWagnerGEffect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illnessAm J Psychiatry199415145165237908501
  • RabkinJGRabkinRWagnerGEffects of fluoxetine on mood and immune status in depressed patients with HIV illnessJ Clin Psychiatry199455392977915270
  • RabkinJGWagnerGJRabkinRFluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trialAm J Psychiatry199915611011079892304
  • TsaiACKarasicDHHammerGPDirectly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trialAm J Public Health2012103230831522720766
  • ZisookSPeterkinJGogginKJSledgePAtkinsonJHGrantITreatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center GroupJ Clin Psychiatry19985952172249632030
  • TsaiACWeiserSDPetersenMLRaglandKKushelMBBangsbergDRA marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIVArch Gen Psychiatry201067121282129021135328
  • KumarVEncinosaWEffects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patientsPsychiatr Q200980313114119387832
  • SchroecksnadelKSarclettiMWinklerCQuality of life and immune activation in patients with HIV-infectionBrain Behav Immun200822688188918261883
  • SevignyJJAlbertSMMcDermottMPEvaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementiaNeurology200463112084209015596754
  • PriceRWBrewBSidtisJRosenblumMScheckACClearyPThe brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complexScience198823948405865923277272
  • KoutsilieriESopperSSchellerCTer MeulenVRiedererPParkinsonism in HIV dementiaJ Neural Transm20021095–676777512111466
  • KoutsilieriESopperSSchellerCTer MeulenVRiedererPInvolvement of dopamine in the progression of AIDS dementia complexJ Neural Transm2002109339941011956960
  • MirsattariSMPowerCNathAParkinsonism with HIV infectionMov Disord19981346846899686775
  • HrisoEKuhnTMasdeuJCGrundmanMExtrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathyAm J Psychiatry199114811155815611681751
  • DunlopOBjørklundRBruunJNEarly psychomotor slowing predicts the development of HIV dementia and autopsy-verified HIV encephalitisActa Neurol Scand2002105427027512004769
  • LetendreSLEllisRJAncesBMMcCutchanJANeurologic complications of HIV disease and their treatmentTop HIV Med2007182455520516524
  • LevineAJHinkinCHAndoKAn exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adultsJ Clin Exp Neuropsychol200830783684318608693
  • KoskiLBrouilletteMJLalondeRComputerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment (*)HIV Med201112847248021395965
  • WagnerGJRabkinREffects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trialJ Clin Psychiatry200061643644010901342
  • NaviaBAPriceRWThe acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infectionArch Neurol198744165693800724
  • McArthurJCHooverDRBacellarHDementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort StudyNeurology19934311224522528232937
  • SacktorNMcDermottMPMarderKHIV-associated cognitive impairment before and after the advent of combination therapyJ Neurovirol20028213614211935465
  • SacktorNThe epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapyJ Neurovirol20028Suppl 211512112491162
  • BhaskaranKMussiniCAntinoriAChanges in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapyAnn Neurol200863221322117894380
  • SternYMcDermottMPAlbertSFactors associated with incident human immunodeficiency virus-dementiaArch Neurol200158347347911255452
  • TozziVBalestraPLorenziniPPrevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohortJ Neurovirol200511326527316036806
  • BolokadzeNGabuniaPEzugbaiaMGatsereliaLKhechiashviliGNeurological complications in patients with HIV/AIDSGeorgian Med News2008165343819124914
  • WojnaVSkolaskyRLHechavarríaRPrevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairmentJ Neurovirol200612535636417065128
  • JowiJOMativoPMMusokeSSClinical and laboratory characteristics of hospitalised patients with neurological manifestations of HIV/AIDS at the Nairobi hospitalEast Afr Med J2007842677617598667
  • HeatonRKCliffordDBFranklinDRJrHIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER StudyNeurology201075232087209621135382
  • McArthurJCSteinerJSacktorNNathAHuman immunodeficiency virus-associated neurocognitive disorders: Mind the gapAnn Neurol201067669971420517932
  • FinziDHermankovaMPiersonTIdentification of a reservoir for HIV-1 in patients on highly active antiretroviral therapyScience19972785341129513009360927
  • AnthonyICRamageSNCarnieFWSimmondsPBellJEInfluence of HAART on HIV-related CNS disease and neuroinflammationJ Neuropathol Exp Neurol200564652953615977645
  • AnthonyICRamageSNCarnieFWSimmondsPBellJEDoes drug abuse alter microglial phenotype and cell turnover in the context of advancing HIV infection?Neuropathol Appl Neurobiol200531332533815885069
  • CysiqueLABrewBJNeuropsychological functioning and antiretroviral treatment in HIV/AIDS: a reviewNeuropsychol Rev200919216918519424802
  • Gonzalez-ScaranoFMartin-GarciaJThe neuropathogenesis of AIDSNat Rev Immunol200551698115630430
  • KaulMHIV’s double strike at the brain: neuronal toxicity and compromised neurogenesisFront Biosci2008132484249417981728
  • HeatonRKFranklinDREllisRJHIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsJ Neurovirol201017131621174240
  • DoreGJCorrellPKLiYKaldorJMCooperDABrewBJChanges to AIDS dementia complex in the era of highly active antiretroviral therapyAIDS199913101249125310416530
  • SkinnerSAdewaleAJDeBlockLGillMJPowerCNeurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapyHIV Med200910424625219187172
  • HasbunRErasoJRamireddySScreening for neurocognitive impairment in HIV individuals: the utility of the Montreal Cognitive Assessment TestJ AIDS Clin Res201331018623956944
  • GandhiNSMoxleyRTCreightonJComparison of scales to evaluate the progression of HIV-associated neurocognitive disorderHIV Ther20104337137920824119
  • DavisHFSkolaskyRLJrSelnesOABurgessDMMcArthurJCAssessing HIV-associated dementia: modified HIV dementia scale versus the Grooved PegboardAIDS Read200212129313811862658
  • OshinaikeOOAkinbamiAAOjoOOOjiniIFOkubadejoUNDanesiAMComparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral TherapyAIDS Res Treat2012201258153123050130
  • DescampsMHyareHZerizerIJ A GerHNeuroimaging of CNS involvement in HIVJ HIV Ther2008133485419039295
  • RocACAncesBMChawlaSDetection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapyArch Neurol20076491249125717620480
  • ThurnherMMSchindlerEGThurnherSAPernerstorfer-SchonHKleibl-PopovCRiegerAHighly active antiretroviral therapy for patients with AIDS dementia complex: effect on MR imaging findings and clinical courseAJNR Am J Neuroradiol200021467067810782776
  • DescampsMHyareHStebbingJWinstonAMagnetic resonance imaging and spectroscopy of the brain in HIV diseaseJ HIV Ther2008133555819039299
  • SundgrenPCDongQGomez-HassanDMukherjiSKMalyPWelshRDiffusion tensor imaging of the brain: review of clinical applicationsNeuroradiology200446533935015103435
  • ChangLLeePLYiannoutsosCTA multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to ageNeuroimage20042341336134715589098
  • MohamedMABarkerPBSkolaskyRLBrain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy studyMagn Reson Imaging20102891251125720688449
  • YiannoutsosCTErnstTChangLRegional patterns of brain metabolites in AIDS dementia complexNeuroimage200423392893515528093
  • MeyerhoffDJMacKaySBachmanLReduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: in vivo 1H magnetic resonance spectroscopic imagingNeurology1993433 pt 15095158450992
  • ErnstTChangLJovicichJAmesNArnoldSAbnormal brain activation on functional MRI in cognitively asymptomatic HIV patientsNeurology20025991343134912427881
  • SchifittoGKieburtzKMcDermottMPClinical trials in HIV-associated cognitive impairment: cognitive and functional outcomesNeurology200156341541811171916
  • UthmanOAAbdulmalikJOAdjunctive therapies for AIDS dementia complexCochrane Database Syst Rev20083CD00649618646159
  • Robinson-PappJElliottKJSimpsonDMHIV-related neurocognitive impairment in the HAART eraCurr HIV/AIDS Rep20096314615219589300
  • TozziVBalestraPSerrainoDNeurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAARTAIDS Res Hum Retroviruses200521870671316131310
  • WinstonAPulsRKerrSJDynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled studyHIV Med201113424525122151608
  • RourkeSBHalmanMHBasselCNeurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioningJ Clin Exp Neuropsychol199921673775610649531
  • HeseltinePNGoodkinKAtkinsonJHRandomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairmentArch Neurol199855141519443710
  • ConsortiumDA randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive DisordersNeurology19985036456519521250
  • SchifittoGNaviaBAYiannoutsosCTAdult AIDS Clinical Trial Group (ACTG) 301, 700 Teams, HIV MRS ConsortiumMemantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy studyAIDS200721141877188617721095
  • KieburtzKDGiangDWSchifferRBVakilNAbnormal vitamin B12 metabolism in human immunodeficiency virus infection. Association with neurological dysfunctionArch Neurol19914833123141848071
  • MintzMTardieuMHoytLMcSherryGMendelsonJOleskeJLevodopa therapy improves motor function in HIV-infected children with extrapyramidal syndromesNeurology1996476158315858960752
  • HinkinCHCastellonSAHardyDJFarinpourRNewtonTSingerEMethylphenidate improves HIV-1-associated cognitive slowingJ Neuropsychiatry Clin Neurosci200113Spring 224825411449032
  • CzubSKoutsilieriESopperSEnhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugsActa Neuropathol20011012859111271377
  • DettlingMMuller-OerlinghausenBBritschPClozapine treatment of HIV-associated psychosis – too much bone marrow toxicity?Pharmacopsychiatry19983141561579754853
  • ZilikisNNimatoudisIKiossesVIerodiakonouCTreatment with risperidone of an acute psychotic episode in a patient with AIDSGen Hosp Psychiatry19982063843859854654